GlaxoSmithKline has agreed a $3.3 billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with companies ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from ...

After a period of unsteady sales for its key COVID-19 products, Pfizer now sees COVID-related revenue volatility as “largely in the past.”  | The company benefited from higher-than-expected sales of ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes ... funding from Wyeth/Pfizer, GSK, is a member of advisory ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

The partnership intends to create a vaccine or vaccines which target cells at the pre-cancerous stage before the disease has taken hold and begun to wreak havoc on the body The University of ...